Every 424B that SeaStar Medical Holding Corporation (ICU) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow ICU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ICU filings page.
SeaStar Medical Holding Corporation registered 1,664,543 shares of Common Stock for resale by Lincoln Park Capital Fund, LLC under a resale prospectus; these shares are being offered for resale by the selling stockholder.
The resale is by Lincoln Park and the Company will receive no proceeds from those resales. The Company may, however, receive up to $14,657,887.43 aggregate gross proceeds (in addition to $342,112.57 previously received) under the April 25, 2025 Purchase Agreement if it elects to sell shares to Lincoln Park. As of April 20, 2026, SeaStar had 3,997,002 shares outstanding and Lincoln Park’s purchases are subject to a 4.99% beneficial ownership cap (which Lincoln Park may increase to 9.99% with 61 days’ notice).
SeaStar Medical Holding Corporation is registering the offer and sale of up to $1,901,000 of its common stock under an at-the-market program with H.C. Wainwright & Co. acting as sales agent. The company previously established an ATM facility with an aggregate offering price of $2,279,989, of which $1,170,258 of common stock had been sold as of November 6, 2025. This supplement amends the prior prospectus to align the maximum amount that may be sold with the limits of General Instruction I.B.6 of Form S-3, which currently permits offerings up to an aggregate price of $1,901,390. SeaStar’s public float held by non-affiliates is stated as $44,394,521, based on 35,802,033 shares at $1.24 per share, and the company notes it has sold $12,896,813 of common stock under these I.B.6 limits over the prior 12-month period.
SeaStar Medical Holding Corporation launched an at‑the‑market offering of up to $2,279,989 of common stock under its S‑3 shelf, with H.C. Wainwright as sales agent. Sales may be made on Nasdaq or otherwise at prevailing prices. Wainwright will receive a 3.0% cash commission on gross sales, and will be deemed an underwriter for these transactions.
The company intends to use net proceeds for general corporate purposes. As of October 10, 2025, ICU last traded at $0.5716 and its listed warrants at $0.0301. SeaStar notes its public float was $42,019,639 (33,886,805 non‑affiliate shares at $1.24) and that it remains subject to Form S‑3 I.B.6 limits; it sold $11,726,556 over the prior 12 months. Nasdaq has notified the company of $1.00 minimum bid non‑compliance; SeaStar has until January 27, 2026 to regain compliance. If all ATM shares were sold at $0.5716, common stock outstanding would rise to up to 38,085,204 shares; the actual number depends on sale prices.